Esonaaf 40 mg (Capsule (Enteric Coated))

Title

• Esonaaf 40 mg Capsule

Categories

• Medicine
• Healthcare
• Pharmaceutical

Description

• Proton pump inhibitor for treating GERD and related conditions

Dosage Form

• Oral
• IV Injection
• IV infusion
• Oral Suspension

Dosage Instructions

• 20 mg or 40 mg Once Daily for healing of erosive esophagitis for 4-8 Weeks
• 20 mg Once Daily for maintenance of healing of erosive esophagitis
• 20 mg Once Daily for Symptomatic GERD for 4 Weeks
• 40 mg Once Daily for Helicobacter Pylori eradication for 10 days
• 20-80 mg once daily for Zollinger-Ellison Syndrome
• 20-40 mg once daily for Acid-related Dyspepsia for 2-4 weeks
• 20 mg once daily for Duodenal ulcer for 2-4 weeks; 20-40 mg once daily for Gastric ulcer for 4-8 weeks

Administration Instructions

• Tablet or capsule should be swallowed whole and taken one hour before a meal
• Oral suspension to be taken with water, with specific instructions for administration through a nasogastric or gastric tube
• IV Injection to be administered over a period of at least 3 minutes
• Precautions for y swallowing capsules
• Use of antacids while taking Esonaaf

Indications

• Relief from chronic heartburn symptoms
• Healing of erosive esophagitis
• Maintenance of healing of erosive esophagitis
• Eradication of Helicobacter pylori infection in patients with duodenal ulcer disease
• Treatment of Zollinger-Ellison Syndrome
• Management of Acid related Dyspepsia
• Treatment of Duodenal & Gastric ulcer

Pharmacology

• Proton pump inhibitor
• Suppression of gastric acid secretion
• Absorption, Distribution, Metabolism, Excretion of Esomeprazole
• Combination therapy with antimicrobials
• Plasma protein binding
• Metabolism by CYP2C19 and CYP3A4 enzymes

Interaction

• Metabolism in the liver by CYP2C19 and CYP3A4
• No clinically relevant interactions with specific CYP enzymes expected
• Potential interference with absorption of drugs affected by gastric pH

Contraindications

• Known hypersensitivity to any of the formulation

Side Effects

• Headache
• Diarrhoea
• Nausea
• Flatulence
• Abdominal pain
• Constipation
• Dry mouth
• Similar side effects during maintenance treatment

Pregnancy & Lactation

• No adequate and well-controlled studies in pregnant women
• No excretion studies in milk
• Discontinuation of breast-feeding if essential

Precautions & Warnings

• Symptomatic response does not exclude gastric malignancy
• Instructions for patients with difficulty swallowing capsules
• Use of antacids while taking Esonaaf

Use in Special Populations

• Safety and effectiveness not established in paediatric patients
• No overall differences in safety and efficacy between elderly and younger individuals
• No recommended dosage adjustment for patients with mild to moderate hepatic insufficiency
• No expected alteration in pharmacokinetics for patients with renal impairment

Overdose Effects

• Lethal dose observed in rats
• Reduced motor activity, respiratory frequency changes, tremor, ataxia, clonic convulsions
• No specific antidote known
• Symptomatic and supportive treatment recommended

Storage Conditions

• Temperature not exceeding 30°C
• Dry place
• Protection from light and moisture
• Keep out of reach of children

Chemical Structure

• Molecular Formula: C17H19N3O3S
• Chemical Structure Image

Commonly Asked Questions

• Description of Esonaaf 40 mg Capsule
• Uses of Esonaaf 40 mg Capsule
• Side effects of Esonaaf 40 mg Capsule
• Pregnancy and breastfeeding concerns
• Onset of action of Esonaaf
• Quick Tips

Related Brands

• Nexven 20 mg (Capsule (Enteric Coated)) - c2c-pharma-ltd